Candel Therapeutics Inc. (CADL)
NASDAQ · Healthcare
Candel Therapeutics Inc. EBITDA 2020–2022
Candel Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2020 to 2022. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Candel Therapeutics Inc. ebitda for the quarter ending September 30, 2022 was -8.7 M, a 8.42% increase year-over-year.
- Candel Therapeutics Inc. ebitda for the twelve months ending September 30, 2022 was -34.1 M, a 123.69% increase year-over-year.
- Candel Therapeutics Inc. annual ebitda for 2022 was -33.9 M, a 33.15% increase from 2021.
- Candel Therapeutics Inc. annual ebitda for 2021 was -25.5 M, a 85.83% increase from 2020.
- Candel Therapeutics Inc. annual ebitda for 2020 was -13.7 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Candel Therapeutics Inc. EBITDA — FAQ
Candel Therapeutics Inc. (CADL) ebitda over the last 3 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CADL's ebitda history?
The chart and table above show Candel Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.